JP2018525425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525425A5 JP2018525425A5 JP2018510912A JP2018510912A JP2018525425A5 JP 2018525425 A5 JP2018525425 A5 JP 2018525425A5 JP 2018510912 A JP2018510912 A JP 2018510912A JP 2018510912 A JP2018510912 A JP 2018510912A JP 2018525425 A5 JP2018525425 A5 JP 2018525425A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- formula
- solvate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000012453 solvate Substances 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 206010009944 Colon cancer Diseases 0.000 claims description 15
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims description 10
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 10
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims description 10
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 10
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 10
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000004931 neurofibromatosis Diseases 0.000 claims description 5
- 230000002018 overexpression Effects 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000000649 small cell carcinoma Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 150000003890 succinate salts Chemical class 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- -1 2-amino-4-pyrimidinyl Chemical group 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562211027P | 2015-08-28 | 2015-08-28 | |
| US62/211,027 | 2015-08-28 | ||
| PCT/IB2016/055076 WO2017037587A1 (en) | 2015-08-28 | 2016-08-25 | Combination of ribociclib and dabrafenib for treating or preventing cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018525425A JP2018525425A (ja) | 2018-09-06 |
| JP2018525425A5 true JP2018525425A5 (enExample) | 2019-10-03 |
Family
ID=56896743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510912A Withdrawn JP2018525425A (ja) | 2015-08-28 | 2016-08-25 | がんを治療または予防するためのリボシクリブとダブラフェニブの組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20180250302A1 (enExample) |
| EP (1) | EP3340987A1 (enExample) |
| JP (1) | JP2018525425A (enExample) |
| CN (1) | CN108348513A (enExample) |
| WO (1) | WO2017037587A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018051306A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| KR20240032157A (ko) | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
| AU2019407159A1 (en) * | 2018-12-20 | 2021-07-15 | Novartis Ag | Combination therapy with a Raf inhibitor and a CKD4/6 inhibitor for use in the treatment of cancer |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| CN119632992A (zh) * | 2019-06-21 | 2025-03-18 | 帕特恩电脑公司 | 用于治疗癌症的治疗性组合物和方法 |
| CN115551509A (zh) * | 2020-05-12 | 2022-12-30 | 诺华股份有限公司 | 包含craf抑制剂的治疗组合 |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
| WO2025219830A1 (en) * | 2024-04-15 | 2025-10-23 | Novartis Ag | Pharmaceutical compositions of ribociclib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| KR101353857B1 (ko) | 2008-08-22 | 2014-01-21 | 노파르티스 아게 | Ｃｄｋ 억제제로서 피롤로피리미딘 화합물 |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
-
2016
- 2016-08-25 JP JP2018510912A patent/JP2018525425A/ja not_active Withdrawn
- 2016-08-25 US US15/755,270 patent/US20180250302A1/en not_active Abandoned
- 2016-08-25 EP EP16763589.5A patent/EP3340987A1/en not_active Withdrawn
- 2016-08-25 CN CN201680062281.0A patent/CN108348513A/zh active Pending
- 2016-08-25 WO PCT/IB2016/055076 patent/WO2017037587A1/en not_active Ceased
-
2020
- 2020-10-19 US US17/074,120 patent/US20210186973A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525425A5 (enExample) | ||
| JP2018526376A5 (enExample) | ||
| CN103402519B (zh) | 肿瘤治疗剂 | |
| JP2015508103A5 (enExample) | ||
| JP2019511528A5 (enExample) | ||
| JP2013510125A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016526540A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2019528307A5 (enExample) | ||
| JP2019510787A5 (enExample) | ||
| JP2016514719A5 (enExample) | ||
| JP2014507464A5 (enExample) | ||
| JP2012526766A5 (enExample) | ||
| JP2015500885A5 (enExample) | ||
| KR102708246B1 (ko) | 식도암을 치료하기 위한 퀴놀린 유도체의 용도 및 치료방법, 이의 약제학적 조성물 및 키트 | |
| JP2012522841A5 (enExample) | ||
| JP2015536997A5 (enExample) | ||
| JP2014506582A5 (enExample) | ||
| JP2017507175A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| JP2011524362A5 (enExample) | ||
| CA2914742A1 (en) | Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception | |
| JP2016502540A5 (enExample) | ||
| JP2013507382A5 (enExample) |